Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEND: Memantine in Mild and Moderate Traumatic Brain Injury
NCT07867210Phase 2Not yet recruiting
- Sponsor
- Nova Scotia Health
- Start
- Jun 2027
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of memantine in traumatic brain injury (TBI) (3 arms), sponsored by Nova Scotia Health. Primary endpoint: Number of Participants Randomized at 24 months. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
memantine
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT07867210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07867210.